Skip to main content
Top
Published in: Osteoporosis International 11/2010

01-11-2010 | Original Article

Therapy of hypoparathyroidism with intact parathyroid hormone

Authors: M. R. Rubin, J. Sliney Jr., D. J. McMahon, S. J. Silverberg, J. P. Bilezikian

Published in: Osteoporosis International | Issue 11/2010

Login to get access

Abstract

Summary

Hypoparathyroidism, a disorder characterized by low parathyroid hormone (PTH), is generally treated with oral calcium and vitamin D supplementation. We investigated the effects of PTH(1–84) treatment in 30 hypoparathyroid subjects for 24 months. PTH(1–84) treatment in hypoparathyroidism significantly reduced supplemental calcium and 1,25-dihydroxyvitamin D requirements without generally altering serum and urinary calcium levels.

Introduction

Hypoparathyroidism, a disorder characterized by low PTH, is associated with hypocalcemia, hypercalciuria, and increased bone mineral density (BMD). Conventional therapy with calcium and 1,25-dihydroxyvitamin D can maintain the serum calcium concentration, but doses are high, and control is variable. We investigated the effects of human PTH(1–84) treatment in hypoparathyroidism.

Methods

Thirty subjects with hypoparathyroidism were treated in an open-label study of PTH(1–84) 100 µg every other day by subcutaneous injection for 24 months, with monitoring of calcium and vitamin D supplementation requirements, serum and 24 h urinary calcium excretion, and BMD by dual energy X-ray absorptiometry.

Results

Requirements for supplemental calcium decreased significantly (3,030 ± 2,325 to 1,661 ± 1,267 mg/day (mean ± SD); p < 0.05), as did requirements for supplemental 1,25-dihydroxyvitamin D (0.68 ± 0.5 to 0.40 ± 0.5 µg/day; p < 0.05). Serum calcium levels and 24 h urinary calcium excretion were mostly unchanged at 24 months. BMD increased at the lumbar spine by 2.9 ± 4% from baseline (p < 0.05), while femoral neck BMD remained unchanged and distal one third radial BMD decreased by 2.4 ± 4% (p < 0.05).

Conclusion

PTH(1–84) treatment in hypoparathyroidism significantly reduces supplemental calcium and 1,25-dihydroxyvitamin D requirements without generally altering serum and urinary calcium levels.
Literature
1.
2.
go back to reference Thakker R (2004) Genetics of endocrine and metabolic disorders: parathyroid. Rev Endocr Metab Disord 5:37–51CrossRefPubMed Thakker R (2004) Genetics of endocrine and metabolic disorders: parathyroid. Rev Endocr Metab Disord 5:37–51CrossRefPubMed
3.
go back to reference Rubin M, Levine M (2008) Hypoparathyroidism. In: Primer of metabolic bone diseases. American Society of Bone and Mineral Research, Washington Rubin M, Levine M (2008) Hypoparathyroidism. In: Primer of metabolic bone diseases. American Society of Bone and Mineral Research, Washington
4.
go back to reference Kao PC, van Heerden JA, Grant CS, Klee GG, Khosla S (1992) Clinical performance of parathyroid hormone immunometric assays. Mayo Clin Proc 67:637–645PubMed Kao PC, van Heerden JA, Grant CS, Klee GG, Khosla S (1992) Clinical performance of parathyroid hormone immunometric assays. Mayo Clin Proc 67:637–645PubMed
5.
go back to reference Michelangeli VP, Heyma P, Colman PG, Ebeling PR (1997) Evaluation of a new, rapid and automated immunochemiluminometric assay for the measurement of serum intact parathyroid hormone. Ann Clin Biochem 34(Pt 1):97–103PubMed Michelangeli VP, Heyma P, Colman PG, Ebeling PR (1997) Evaluation of a new, rapid and automated immunochemiluminometric assay for the measurement of serum intact parathyroid hormone. Ann Clin Biochem 34(Pt 1):97–103PubMed
6.
go back to reference Christiansen C, Rodbro P, Christensen MS, Hartnack B, Transbol I (1978) Deterioration of renal function during treatment of chronic renal failure with 1, 25-dihydroxycholecalciferol. Lancet 2:700–703CrossRefPubMed Christiansen C, Rodbro P, Christensen MS, Hartnack B, Transbol I (1978) Deterioration of renal function during treatment of chronic renal failure with 1, 25-dihydroxycholecalciferol. Lancet 2:700–703CrossRefPubMed
8.
go back to reference Litvak J, Moldawer MP, Forbes AP, Henneman PH (1958) Hypocalcemic hypercalciuria during vitamin D and dihydrotachysterol therapy of hypoparathyroidism. J Clin Endocrinol Metab 18:246–252CrossRefPubMed Litvak J, Moldawer MP, Forbes AP, Henneman PH (1958) Hypocalcemic hypercalciuria during vitamin D and dihydrotachysterol therapy of hypoparathyroidism. J Clin Endocrinol Metab 18:246–252CrossRefPubMed
9.
go back to reference Winer KK, Ko CW, Reynolds JC et al (2003) Long-term treatment of hypoparathyroidism: a randomized controlled study comparing parathyroid hormone-(1–34) versus calcitriol and calcium. J Clin Endocrinol Metab 88:4214–4220CrossRefPubMed Winer KK, Ko CW, Reynolds JC et al (2003) Long-term treatment of hypoparathyroidism: a randomized controlled study comparing parathyroid hormone-(1–34) versus calcitriol and calcium. J Clin Endocrinol Metab 88:4214–4220CrossRefPubMed
10.
go back to reference Winer KK, Yanovski JA, Cutler GB Jr (1996) Synthetic human parathyroid hormone 1–34 vs calcitriol and calcium in the treatment of hypoparathyroidism. JAMA 276:631–636CrossRefPubMed Winer KK, Yanovski JA, Cutler GB Jr (1996) Synthetic human parathyroid hormone 1–34 vs calcitriol and calcium in the treatment of hypoparathyroidism. JAMA 276:631–636CrossRefPubMed
11.
go back to reference Winer KK, Yanovski JA, Sarani B, Cutler GB Jr (1998) A randomized, cross-over trial of once-daily versus twice-daily parathyroid hormone 1–34 in treatment of hypoparathyroidism. J Clin Endocrinol Metab 83:3480–3486CrossRefPubMed Winer KK, Yanovski JA, Sarani B, Cutler GB Jr (1998) A randomized, cross-over trial of once-daily versus twice-daily parathyroid hormone 1–34 in treatment of hypoparathyroidism. J Clin Endocrinol Metab 83:3480–3486CrossRefPubMed
12.
go back to reference Nussbaum SR, Zahradnik RJ, Lavigne JR et al (1987) Highly sensitive two-site immunoradiometric assay of parathyrin, and its clinical utility in evaluating patients with hypercalcemia. Clin Chem 33:1364–1367PubMed Nussbaum SR, Zahradnik RJ, Lavigne JR et al (1987) Highly sensitive two-site immunoradiometric assay of parathyrin, and its clinical utility in evaluating patients with hypercalcemia. Clin Chem 33:1364–1367PubMed
13.
go back to reference Neer RM, Arnaud CD, Zanchetta JR et al (2001) Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434–1441CrossRefPubMed Neer RM, Arnaud CD, Zanchetta JR et al (2001) Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434–1441CrossRefPubMed
Metadata
Title
Therapy of hypoparathyroidism with intact parathyroid hormone
Authors
M. R. Rubin
J. Sliney Jr.
D. J. McMahon
S. J. Silverberg
J. P. Bilezikian
Publication date
01-11-2010
Publisher
Springer-Verlag
Published in
Osteoporosis International / Issue 11/2010
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-009-1149-x

Other articles of this Issue 11/2010

Osteoporosis International 11/2010 Go to the issue